Evidence map›Paper›PMID 34599188›Full record

ReviewNPJ Regenerative medicine2021

Tendon and multiomics: advantages, advances, and opportunities.

Paula Sarmiento, Dianne Little

Abstract readReview
In one paragraph

Review in NPJ Regenerative medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Achilles tendinopathy.Nature reviews. Disease primers · 2025
    Review
  4. Review
  5. Tendon mechanobiology in the context of tendon biofabrication.Frontiers in bioengineering and biotechnology · 2025
    Review
  6. Article
  7. Recombinant lysyl oxidase effects on embryonic tendon cell phenotype and behavior.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Tendon mechanical properties are enhancedFrontiers in bioengineering and biotechnology · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paula SarmientoWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA. psarmien@purdue.edu.
Dianne LittleWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA. little33@purdue.edu.ORCID http://orcid.org/0000-0002-1869-7083

Funding

Driver Genes for Engineered Rotator Cuff DevelopmentR01AR073882 · NIAMS · PURDUE UNIVERSITY · PI LITTLE, DIANNE · 2019 to 2023
$2.4M
NIAMS NIH HHS R01 AR073882U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR073882
6 · The paper itself

Abstract

Tendons heal by fibrosis, which hinders function and increases re-injury risk. Yet the biology that leads to degeneration and regeneration of tendons is not completely understood. Improved understanding of the metabolic nuances that cause diverse outcomes in tendinopathies is required to solve these problems. 'Omics methods are increasingly used to characterize phenotypes in tissues. Multiomics integrates 'omic datasets to identify coherent relationships and provide insight into differences in molecular and metabolic pathways between anatomic locations, and disease stages. This work reviews the current literature pertaining to multiomics in tendon and the potential of these platforms to improve tendon regeneration. We assessed the literature and identified areas where 'omics platforms contribute to the field: (1) Tendon biology where their hierarchical complexity and demographic factors are studied. (2) Tendon degeneration and healing, where comparisons across tendon pathologies are analyzed. (3) The in vitro engineered tendon phenotype, where we compare the engineered phenotype to relevant native tissues. (4) Finally, we review regenerative and therapeutic approaches. We identified gaps in current knowledge and opportunities for future study: (1) The need to increase the diversity of human subjects and cell sources. (2) Opportunities to improve understanding of tendon heterogeneity. (3) The need to use these improvements to inform new engineered and regenerative therapeutic approaches. (4) The need to increase understanding of the development of tendon pathology. Together, the expanding use of various 'omics platforms and data analysis resulting from these platforms could substantially contribute to major advances in the tendon tissue engineering and regenerative medicine field.

Identifiers

PMID34599188
PMCPMC8486786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.